Search Results - "Fortmann, Seth"
-
1
AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration
Published in Molecular therapy (07-02-2018)“…Sustained suppression of VEGF is needed in many patients with neovascular age-related macular degeneration (NVAMD), and gene transfer of a VEGF-neutralizing…”
Get full text
Journal Article -
2
Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy
Published in Diabetologia (01-09-2023)“…Aims/hypothesis Hyper-reflective crystalline deposits found in retinal lesions have been suggested to predict the progression of diabetic retinopathy, but the…”
Get full text
Journal Article -
3
Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis
Published in International journal of molecular sciences (15-08-2022)“…The gut is a well-established route of infection and target for viral damage by SARS-CoV-2. This is supported by the clinical observation that about half of…”
Get full text
Journal Article -
4
Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Published in Blood (10-08-2023)“…Tyrosine kinase inhibitors (TKIs) are very effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent leukemia stem cells persist as a…”
Get full text
Journal Article -
5
The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization
Published in Journal of molecular medicine (Berlin, Germany) (01-04-2017)“…Acriflavine, a fluorescent drug previously used for bacterial and trypanosomal infections, reduces hypoxia-inducible factor-1 (HIF-1) and HIF-2 transcriptional…”
Get full text
Journal Article -
6
Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths
Published in The American journal of medicine (01-06-2017)Get full text
Journal Article -
7
Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage
Published in Science translational medicine (18-01-2017)“…Vascular endothelial growth factor (VEGF)-neutralizing proteins provide benefit in several retinal and choroidal vascular diseases, but some patients still…”
Get more information
Journal Article -
8
Reversible retinal vessel closure from VEGF-induced leukocyte plugging
Published in JCI insight (21-09-2017)“…Clinical trials in patients with macular edema due to diabetic retinopathy or retinal vein occlusion (RVO) have shown that suppression of VEGF not only…”
Get full text
Journal Article -
9
Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models
Published in Scientific reports (23-04-2018)“…Vitreous or aqueous humour taps are widely used in patients or large animals with retinal diseases to monitor disease biomarkers, search for novel biomarkers,…”
Get full text
Journal Article -
10
Molecular mechanisms of retinal ischemia
Published in Current opinion in physiology (01-02-2019)“…•In addition to oxygen deprivation, HIF-1α stabilization is also highly dependent upon the metabolic status of the cell.•β-oxidation is a prominent feature of…”
Get full text
Journal Article -
11
The FDA report on vorapaxar in the elderly: A convoluted dilemma
Published in International journal of cardiology (15-12-2015)“…Abstract There are consistent data suggesting that elderly patients benefit from less aggressive antiplatelet strategies following acute coronary syndromes…”
Get full text
Journal Article -
12
The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity
Published in Investigative ophthalmology & visual science (01-02-2017)“…To investigate the role of nicotinic acetylcholine receptors (nAChRs) in retinal vascular development and ischemia-induced retinal neovascularization (NV). The…”
Get full text
Journal Article -
13
Vorapaxar and optimal aspirin dose: The FDA outlook
Published in International journal of cardiology (15-01-2016)“…Abstract Vorapaxar, a novel thrombin PAR-1 inhibitor, approved for post-myocardial infarction, and peripheral artery disease indications has been tested in 2…”
Get full text
Journal Article -
14
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge
Published in Thrombosis and haemostasis (01-01-2014)“…The recently published, largest trial with cangrelor, the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition…”
Get more information
Journal Article -
15
Interferon-dependent signaling is critical for viral clearance in airway neutrophils
Published in JCI insight (22-05-2023)“…Neutrophilic inflammation characterizes several respiratory viral infections, including COVID-19-related acute respiratory distress syndrome, although its…”
Get full text
Journal Article -
16
Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19
Published in Blood advances (08-08-2023)“…•To our knowledge, we provide the first evidence implicating SARS-CoV-2+ peripheral blood megakaryocytes in severe disease.•Circulating megakaryocytes warrant…”
Get full text
Journal Article -
17
Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization
Published in FASEB bioAdvances (01-04-2020)“…In patients with macular edema due to ischemic retinopathy, aqueous levels of hepatocyte growth factor (HGF) correlate with edema severity. We tested whether…”
Get full text
Journal Article -
18
Progenitor cell combination normalizes retinal vascular development in the oxygen-induced retinopathy (OIR) model
Published in JCI insight (01-11-2019)“…Retinopathy of prematurity (ROP) is a disorder of the developing retina of preterm infants. ROP can lead to blindness because of abnormal angiogenesis that is…”
Get full text
Journal Article -
19
Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Published in American journal of therapeutics (01-03-2017)“…Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, is currently approved for post myocardial infarction and peripheral artery disease indications with…”
Get full text
Journal Article -
20
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation
Published in Thrombosis and haemostasis (02-05-2016)“…Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, has been evaluated in the successful TRA2P trial and the failed TRACER trial. The drug is currently…”
Get more information
Journal Article